PRESS RELEASE Presentations outline how BluePrint® genomic testing enables further Read More
PRESS RELEASE Median follow up nearing 9 years confirms MINDACT Read More
PRESS RELEASE Data adds to the growing body of evidence Read More
PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test Read More
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
As a valued customer we wanted to reach out and Read More
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Read More
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Read More
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Read More
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
